PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update

Friday, May 3, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Translarna™ Approved by Brazilian Health Regulatory Authority (ANVISA)

PTC Therapeutics, Inc.

Reconciliation of GAAP to Non-GAAP Projected Full Year 2019 R&D and SG&A Expense

(In thousands)

Low End of Range

High End of Range

Projected GAAP R&D and SG&A expense

$

395,000

$

405,000

Less: projected non-cash, stock-based compensation expense

35,000

35,000

Projected non-GAAP R&D and SG&A expense

$

360,000

$

370,000



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store